ProQR Therapeutics
ProQR Therapeutics' revenue fell 15.9% to €16 million in fiscal 2025. Its operating margin was −273.1%, down from −161.2% a year earlier. Free cash flow was −€54 million. The diluted share count rose 22.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.
Income statement
ProQR Therapeutics lost money in fiscal 2025: a net loss of €42 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 188 | 95 | 119 | 149 | 92 |
| Debt incl. finance leases | 49 | — | — | — | — |
| Net debt (negative means net cash) | −139 | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.4x | — | — | — | — |
| Interest coverage | −16.8x | −12.7x | −26.5x | −28.3x | −46.8x |
| Current ratio | 6.9x | 7.4x | 3.5x | 4.0x | 3.1x |
| Quick ratio | 6.9x | 7.4x | 3.5x | 4.0x | 3.1x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 391.0% | −9.8% | −354.2% |
| Altman Z'' | −6.45 | −3.85 | −11.35 |
| Accruals ratio | −32.1% | 5.6% | 7.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Fail | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Fail | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | — | — | — |
Compare
Put ProQR Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| ProQR Therapeutics | FY25 | −15.9% | −273.1% | −338.3% | — | — | — | |
| Opus Genetics | FY25 | 29.1% | −271.9% | — | — | — | 3 | Compare |
| Pyxis Oncology | FY25 | −14.2% | −609.2% | −458.3% | — | — | — | Compare |
| Tonix Pharmaceuticals | FY25 | 29.9% | −959.0% | −787.5% | — | — | — | Compare |
| Sol-Gel Technologies | FY25 | 68.0% | −38.9% | 1.4% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | — | — | — | 1 | 4 | 6 | 19 | 16 |
| Revenue growth | — | — | — | — | — | — | 169.2% | 81.2% | 190.2% | −15.9% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 32 | 31 | 30 | 46 | 38 | 42 | 51 | 25 | 36 | 45 |
| Operating income | −40 | −40 | −36 | −57 | −42 | −57 | −65 | −32 | −30 | −43 |
| Net income | −39 | −44 | −37 | −56 | −47 | −61 | −64 | −28 | −28 | −42 |
| Diluted EPS (EUR) | −1.67 | −1.72 | −1.08 | −1.38 | −0.93 | −0.95 | −0.90 | −0.35 | −0.32 | −0.40 |
| Diluted shares (millions) | 23 | 25 | 34 | 41 | 50 | 64 | 72 | 81 | 86 | 105 |
| Cash flow | ||||||||||
| Cash from operations | −34 | −35 | −28 | −44 | −47 | −26 | −68 | 22 | −36 | −53 |
| Capital expenditure | 2 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| Free cash flow | −37 | −35 | −29 | −45 | −48 | −26 | −69 | 20 | −38 | −54 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 4 | 5 | 9 | 8 | 6 | 3 | 3 | 2 | 4 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 59 | 48 | 106 | 112 | 76 | 188 | 95 | 119 | 149 | 92 |
| Debt incl. finance leases | 6 | 7 | — | 13 | 17 | 49 | — | — | — | — |
| Total assets | 66 | 53 | 110 | 118 | 99 | 210 | 171 | 138 | 168 | 113 |
| Total liabilities | 12 | 14 | 18 | 24 | 42 | 96 | 105 | 96 | 79 | 63 |
| Shareholders' equity | 53 | 39 | 93 | 94 | 57 | 114 | 67 | 41 | 89 | 49 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | −4,285.4% | −1,813.0% | −489.1% | −161.2% | −273.1% |
| Net margin | — | — | — | — | — | −4,549.8% | −1,792.5% | −431.7% | −146.9% | −265.2% |
| Free cash flow margin | — | — | — | — | — | −1,984.7% | −1,925.9% | 309.8% | −200.0% | −338.3% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | −1,756.7% | 391.0% | −9.8% | −354.2% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | −94.3% | −55.8% | −60.3% | −61.5% | −71.1% | −71.2% | −51.9% | −42.7% | −61.2% |
| Return on assets | — | −73.6% | −45.2% | −49.6% | −43.1% | −39.4% | −33.8% | −18.2% | −18.2% | −30.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |